Speaking at the World Health Organization's executive board meeting on October 6, the agency's Director-General Tedros Adhanom Ghebreyesus said "there is hope" that a vaccine against COVID-19 may be ready by the end of this year. During his closing remarks, Tedros called for solidarity an...
COVID-19 pandemicVACCINESB African countries face a number of financial and logistical hurdles. b The struggle to get Covid vaccine to the world's population has often been likened to a race - in which case, Africa finds itself hobbled by an array of financial, technical and cultural ...
As for the concerns about whether the acute hepatitis could be linked to COVID-19 or COVID-19 vaccines, the WHO and some countries have a preliminary conclusion, and the answer is no. "Based on current information, most of the reported children did not receive the COVID-19 vaccine, rulin...
Vaccine (Vero Cell)、康希诺的腺病毒载体新冠疫苗Ad5-nCoV、以及三叶草生物的联合佐剂使用的三聚体重组蛋白新冠疫苗SCB-2019已经完成了受理和专家会议评审程序,正在进行第三阶段临床试验病例审核。 智飞生物新冠疫苗Recombinant Novel Coronavirus Vaccine ...
GENEVA, May 19 (Xinhua) -- The World Health Organization (WHO) validated on Thursday the CONVIDECIA COVID-19 vaccine developed by Chinese developer CanSino Biologics for emergency use, making it the third Chinese vaccine after Sinopharm and Sinopec having been certified by WHO Emergency Use Listin...
根据WHO官网3月2日更新的新冠疫苗紧急使用名单(Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process),目前WHO共批准了10种新冠疫苗的紧急使用,来自辉瑞、阿斯利康、强生、Moderna、Novavax、Bharat Biotech、北京生物、中国生物制药等企业。
CONVIDECIA, administered as a single dose, "is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2," the virus behind COVID-19. The vaccine was found to have 64 percent efficacy against symptomatic disease and 92 percent against severe COVID-19. ...
根据WHO官网3月2日更新的新冠疫苗紧急使用名单(Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process),目前WHO共批准了10种新冠疫苗的紧急使用,来自辉瑞、阿斯利康、强生、Moderna、Novavax、Bharat Biotech、北京生物、中国生物制药等企业。
The World Health Organization, with the support of the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), continues to review and assess the public health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the perfor...
CONVIDECIA, administered as a single dose, “is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2,“ the virus behind COVID-19. The vaccine was found to have 64 percent efficacy against symptomatic disease and 92 percent against severe COVID-19. ...